setmelanotide vs semaglutide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial Timeline of FDA approvals for

For many women, finding a sustainable routine that fits into the demands of life with a baby becomes one of the biggest hurdles

Postpartum recovery has a lot of factors, including hormonal changes, sleep deprivation and mental health, which must all be taken into account before starting a medication like this, she says

A little stomach pain one day, a bit worse the next, and tolerable but annoying by the third day can create a sense of complacency

Different Marketing Claims Wegovy was aggressively marketed directly to consumers for weight loss Ozempic marketing technically focused on diabetes but implied weight benefits Social media influencers promoted both (often Ozempic off-label) Marketing materials affect what representations were made to you Example Case Scenarios Scenario A: Type 2 Diabetic on Ozempic Patient: 58-year-old with 10-year diabetes history Prescription: Ozempic 1.0 mg weekly for A1C control Result: Developed severe gastroparesis requiring feeding tube Legal claim: Even for approved use, warnings about gastroparesis were inadequate Scenario B: Weight Loss Patient on Ozempic (Off-Label) Patient: 42-year-old seeking to lose 40 pounds, no diabetes Prescription: Ozempic 2.0 mg (prescribed off-label by weight loss clinic) Result: Chronic vomiting, diagnosed with gastroparesis Legal claim: Off-label promotion and inadequate warnings for weight-loss use Scenario C: Obesity Patient on Wegovy Patient: 35-year-old with BMI 38, prescribed for weight management Prescription: Wegovy escalated to 2.4 mg Result: Intestinal blockage requiring emergency surgery Legal claim: Despite approved use, risks were not adequately disclosed All three scenarios may have valid legal claims , but the specific arguments and evidence will differ

There are populations of [GLP-1] receptors that we havent asked what they do

phase RCT with N = 1000) Vicardostat (previously known as BI 690517) in DM & non DM CKD (EASiKidney, phase 3 RCT, N = 11000 of vicardostat + empagliflozin) Different mechanisms of MR antagonists and ASI